Update on DF/Net
Lisa Ondrejcek and Darryl Pahl
What’s new with DF/Net?

• Continuing our growth
  • Space
  • People
  • Infrastructure
  • Mission
  • Values
  • Vision
New space: Dundas, Ontario

• Moved out of downtown into brand new building in Dundas
• Space for 25
New space: Seattle, Washington

- Added space for 10 additional people
- Enlarged to new space downstairs
People: Data Management & Data Analytics
People: Infrastructure

• Growth in Administration (Finance, IT, HR)
Growth: Introspection

• 2016 was also a year of introspection
• Time to clarify our mission, values, and vision
DFNet's people, products, and services help our global clients realize and recognize the Truth in their endeavors.
Our mission

• DF/Net’s people, products, and services help our global clients realize and recognize the truth in their endeavors.
Our mission

• DF/Net’s people, **products**, and services help our global clients realize and recognize the truth in their endeavors.
Our mission

• DF/Net’s people, products, and services help our global clients realize and recognize the truth in their endeavors.
DataFax in action at DF/Net

<table>
<thead>
<tr>
<th>53 Current Studies</th>
<th>HIV, Malaria, TB, Leishmaniasis, Japanese Encephalitis, Hookworm, Influenza, Oncology, Sleep Apnea, Vision, Cardiovascular, Overactive Bladder, Ebola, Rheumatoid Arthritis, Psoriasis, HPV, Social Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>29,891 Participants</td>
<td></td>
</tr>
<tr>
<td>215 Sites</td>
<td>Bangladesh, Belgium, Botswana, Brazil, Canada England, France, Indonesia, Kenya, Malawi, Mozambique, Netherlands, Peru, Philippines, South Africa, Swaziland, Switzerland, Tanzania Thailand, Uganda, Ukraine, United States, Vietnam</td>
</tr>
<tr>
<td>25 Countries</td>
<td></td>
</tr>
</tbody>
</table>
Our motto

Helping people help people on a global scale.

• We’re not the researchers

• We help researchers progress more quickly, more efficiently, and more assuredly
Helping people help people on a global scale.

**FDA Approves First Medication to Reduce HIV Risk**

People diagnosed with HIV—the human immunodeficiency virus that without treatment develops into AIDS—take antiretroviral medications to control the infection that attacks their immune system.

Now, for the first time, adults who do not have HIV but are at risk of becoming infected can take a medication to reduce the risk of sexual transmission of the virus.

The Food and Drug Administration (FDA) has approved the use of Truvada to be taken once daily and used in combination with safer sex practices to reduce the risk of sexually acquired HIV infection in adults who do not have HIV but are at high risk of becoming infected. HIV is the most common form of AIDS.

In two large clinical trials, daily use of Truvada was shown to significantly reduce the risk of HIV infection:

- By 42 percent in a study sponsored by the National Institute of Health (NIH) of about 3,200 HIV-negative gay and bisexual men and transgender women.
- By about 70 percent in a study sponsored by the University of Washington of about 2,000 heterosexual women in which one partner was HIV-positive and the other was not.

Debra Brown, M.D., Director of the Division of Antiviral Products in FDA, explained that Truvada needs to prevent HIV from establishing itself and replicating in the body. She noted that this is a new approved use for Truvada. It is not a new product. It was approved by FDA in 2004 for use in combination with other medications to treat HIV-infected adults and children. However, the daily oral tablet regimen for Truvada is an option for a pre-exposure prevention strategy that is being studied for its safety and effectiveness in clinical trials. The study world is still in medical advances, along with the availability of more effective antiretroviral drugs, has enabled us to treat it in a chronic disease most of the time.

Recent studies show that Truvada is not only useful as part of a comprehensive prevention plan that includes consistent and correct condom use, risk reduction counseling and screening, regular HIV testing, and treatment of other sexually transmitted infections. Truvada is not a substitute for safer sex practices.

**Person Must Be HIV Negative**

Truvada, produced by Gilead Sciences Inc., is a combination of two antiretroviral medications used to treat HIV-positive individuals. It is used as a treatment for HIV infection. However, the patient also takes a third drug, based on the needs of the patient, which is not part of the Truvada regimen. The patient must be monitored to ensure that he or she is HIV-negative.

- The patient must be monitored to ensure that he or she is HIV-negative.
- The patient must be monitored to ensure that he or she is HIV-negative.
- The patient must be monitored to ensure that he or she is HIV-negative.
Helping people help people on a global scale.

**FDA Approves First Medication to Reduce HIV Risk**

People diagnosed with HIV—the human immunodeficiency virus that without treatment develops into AIDS—take antiretroviral medications to control the infection that attacks their immune system. Now, for the first time, adults who do not have HIV but are at risk of becoming infected can take a medication to reduce the risk of sexual transmission of the virus.

The Food and Drug Administration (FDA) has approved the use of Truvada, a once-daily pill containing two antiretroviral drugs, tenofovir disoproxil fumarate and emtricitabine, along with a non-nucleoside reverse transcriptase inhibitor, and emtricitabine, in adults and children 12 years of age and older with HIV-1 infection and in adults and children 12 years of age and older who are at high risk of acquiring HIV-1 through sexual exposure.

**The Science Behind Truvada**

Truvada was approved by the FDA in 2004 as a medication for the treatment of HIV in combination with other antiretroviral medications. The medication is taken once a day and provides protection against HIV transmission through sexual contact.

**How It Works**

Truvada works by reducing the risk of HIV transmission through sexual contact. It is designed to lower the viral load in the body, making it less likely to be transmitted to another person.

**Side Effects**

The most common side effects of Truvada include nausea, diarrhea, and headache. More severe side effects can include bone loss, kidney problems, and liver problems.

**Future Directions**

Developers of Truvada are continuing to study the medication's effectiveness and are exploring ways to make it more widely available.

**Key Takeaways**

- Truvada is an effective medication for reducing the risk of HIV transmission.
- It is important to follow the recommended dosage and usage instructions.
- Regular medical check-ups are necessary to monitor for side effects and to ensure the medication is effective.

**References**

- FDA. (2020). *FDA Approves First Medication to Reduce HIV Risk*.
Helping people help people on a local scale.

Senior Farmers Market Nutrition Program
Providing eligible seniors with fresh fruits and vegetables from local farmers markets

Eligibility for $40 worth of vouchers:
- Age 60+ (or age 55+ if you are Native American)
- Low income (no more than $1,832 monthly income for one person or $2,470 for two people—add $642 for each additional person)

How to apply:
Beginning April 16, 2016, print an application from the website listed below. Mail your completed application no later than May 15, 2016:

Senior Farmers Market Nutrition Program
140 Lakeside Avenue, Suite A-180
Seattle WA 98125

Your form will be entered into a random selection process. If your name is selected, you will receive your checks by mail by July 1, 2016.

www.agingkingcounty.org/SFMNP/

DIABESITY RESEARCH FOUNDATION
Changing lives by advancing the science of metabolism

Aging and Disability Services, the Area Agency on Aging for King County, plans, coordinates, and advocates for a comprehensive services delivery system for older adults, family caregivers, and people with disabilities in King County.
www.agingkingcounty.org
Helping people help people on a human scale.

A report on how our work supports the most disadvantaged, from programme design & targeting, to monitoring & evaluation and redesign.

**Glossary**

- **Pupil Premium**: An umbrella term for a government initiative that awards schools on a per-pupil basis for a range of criteria that indicate financial deprivation.
- **SEND**: Children who are identified as having special educational needs and disabilities.
Core Values

- Integrity
- Caring
- Creativity
- Collaboration
- Forward Thinking
Our values in action

Caring

• The connection starts with understanding and empathy for trial participants and clinical sites

• We recognize that the participants represent more than data, and that the clinical sites are the front lines of the research
Our values in action

Collaboration

• DF/Net-level: intra- and inter-office
• Being considered a part of the team for Data Management and Data Analytics
• DFUG represents the opportunity to collaborate with users
2014

Chocolate (software) + peanut butter (services): combined, but still two separate ingredients
Chocolate (software) + peanut butter (services): combined, but still two separate ingredients

Let’s blend the ingredients together so that we’re one combined flavor
2014

Chocolate (software) + peanut butter (services): combined, but still two separate ingredients

2015

Let’s blend the ingredients together so that we’re one combined flavor

2016

We’re distinct ingredients, but mixed more equally and deliciously
Forward Thinking

• We use DataFax every day
• It’s in our interests as well as the interest of our clients to move the software forward
• Employing a mix of long-term developers and new people with fresh ideas
Co-op Students in Dundas
Our values in action

Creativity

• There are many ways to get to the same place: visit structures, edit checks, conditional visits, hybrid data collection

• DF/Net does not want to follow a “cookie cutter” approach

• How to balance customization with standardization?
30X reduced codebase - hours off new implementation

+data integrity less user-reliant
Our values in action

Integrity

• We are actively engaged in all projects and have built long-term relationships with our clients

• As the founders, we have personally performed all data management tasks within the company, from data entry to data management to software development

• We believe in our company, and we are dedicated to helping our clients with their research
Our values in action

• Our expertise, experience, and focus is on global public health: *What you do is what we do.*

• Our core values of integrity, caring, collaboration, creativity, and forward thinking are in alignment with existing DataFax users: *We are all in it together.*

• Our proven software and data models may offer alternatives to fill gaps in a variety of settings: *What we do works.*
Our vision

We envision a world in which data is always connected to its human sources and uses.

Data is an abstraction based on individual observations, measurements, and interpretations. When data stays connected to the evidence it's based on, you can explore and question it, gaining insights that would otherwise be lost.

Data is part of a bigger story - a story of exploration and discovery, of human problems and human solutions. We work hard to find the truth in every story.
Connecting People with Data

• The challenge of international data management is how to connect people with data

• Not just more technology, but the right technology that fits the infrastructure, people, and processes

• With the goal of being able to adapt as the infrastructure, people, and processes change

• All the while keeping people connected to the data
An exciting new DataFax project
The Global Health Clinical Consortium (GHCC) is a funding vehicle for global health research. The GHCC is comprised of clinical operations leaders from 14 Product Development Partners (PDPs).
• 132 ongoing and planned trials to develop vaccines, microbicides/preventatives, therapeutic products and diagnostics
• More than 21 disease areas at 295 clinical research sites
Global Health Clinical Consortium

• DF/Net Research is honored to announce that we have been selected as one of 5 Preferred Providers to the GHCC

• DF/Net looks forward to working alongside many of the world’s leaders in clinical research
The Five Preferred Providers

• Quintiles: 32,000 employees
• FHI 360: 4,000 employees
• Emmes Corporation: 500 employees
• Triclinium: ?? employees
• DF/Net: 60 employees
Why DF/Net?

• New preferred providers chosen to fill gaps in the GHCC research agenda
• With Quintiles and their 32,000 employees, what gap could possibly be left for DF/Net to fill?
Deloitte partners with DF/Net

• Deloitte and DF/Net are partners on a 7-year, Multiple Award, Indefinite Quantity, $750M initiative with NIAID’s Division of Clinical Research (DCR)

• Support NIAID’s program to combat bioterrorism and emerging and re-emerging disease threats
DataFax versus Bioterrorism

• Goal is to build infrastructure globally to provide rapid response to emerging health threats

• Requests could come from U.S. Congress, U.S. State Department, Department of Health and Human Services, or the National Institutes of Health
Why DF/Net?

• Deloitte was referred to DF/Net and DataFax because of our ability to work in challenging settings.

• What data management system has proven to work anywhere, anytime, and all the time?
Why this is important to you

• Demonstration of the continued confidence in DF/Net and DataFax
• Acknowledgement of the synergy of developers, data management, and data analytics
• Opportunity to sit at the same table with industry and research leaders to improve the software